Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

Sorafenib 42lenvatinib 21Fluorouracil 16atezolizumab 15Oxaliplatin 14Bevacizumab 13Doxorubicin 12Radiosurgery 11Leucovorin 11Radiofrequency Ablation 10Ethiodized Oil 10pembrolizumab 7Folfox protocol 7sintilimab 6durvalumab 6Radiotherapy 6Nivolumab 6Epirubicin 6Cisplatin 6tremelimumab 5Gemcitabine 5apatinib 4Embolization, Therapeutic 4tislelizumab 3camrelizumab 3cabozantinib 3Tenofovir 3Pharmaceutical Preparations 3Mitomycin 3Magnetic Resonance Spectroscopy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Hepatocellular × icaritin × Clear all
NCT05594927 2024-08-07

BESTPOP

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Recruiting
261 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03236649 2023-02-08

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Terminated
89 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡